Table 1.
Baseline patient and tumor characteristics
| Characteristics | Value |
|---|---|
| Median age, yr (range) | 50 (31–78) |
| Female sex, n (%) | 35 (100) |
| Race, n (%) | |
| White | 32 (91) |
| African American | 3 (9) |
| Triple negative primary tumor, n (%) | 25 (71) |
| Triple negative metastatic tumor, n (%) | 33 (94) |
| Prior lines of chemotherapy for resectable disease preceding metastasesa, n (%) | |
| 0 | 19 (54) |
| 1 | 6 (17) |
| 2 | 1 (3) |
| Not applicable | 9 (26) |
| Prior lines of chemotherapy for metastatic or unresectable diseaseb, n (%) | |
| 0 | 6 (17) |
| 1 | 18 (51) |
| 2 | 4 (11) |
| 3 | 7 (20) |
| ECOG performance status | |
| 0 | 26 (74) |
| 1 | 8 (23) |
| 2 | 1 (3) |
| Median metastatic sites (range) | 3 (1–6) |
| Sites of metastatic disease, n (%) | |
| Lung | 18 (51) |
| Pleural effusion | 2 (6) |
| Liver | 12 (34) |
| Bone | 13 (37) |
| Breast or chest wall | 16 (46) |
| Lymph nodes | 26 (74) |
| Others | 15 (43) |
n = 35.
a
Including chemotherapy for local in‐breast or nodal recurrence that was completely removed by surgery before the diagnosis of metastatic disease.
b
Including chemotherapy for local in‐breast or nodal recurrence not completely removed by surgery.
Abbreviation: ECOG, Eastern Cooperative Oncology Group.